Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $164,441 | 10 | 95.1% |
| Travel and Lodging | $8,468 | 6 | 4.9% |
| Food and Beverage | $33.37 | 1 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| F. Hoffmann-La Roche AG | $158,000 | 8 | $0 (2022) |
| Novartis Pharma AG | $13,630 | 8 | $0 (2019) |
| Eli Lilly and Company | $1,313 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $68,000 | 4 | F. Hoffmann-La Roche AG ($68,000) |
| 2021 | $1,313 | 1 | Eli Lilly and Company ($1,313) |
| 2020 | $30,000 | 1 | F. Hoffmann-La Roche AG ($30,000) |
| 2019 | $73,630 | 11 | F. Hoffmann-La Roche AG ($60,000) |
All Payment Transactions
17 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/01/2022 | F. Hoffmann-La Roche AG | — | Consulting Fee | Cash or cash equivalent | $12,000.00 | General |
| 07/01/2022 | F. Hoffmann-La Roche AG | — | Consulting Fee | Cash or cash equivalent | $12,000.00 | General |
| 04/01/2022 | F. Hoffmann-La Roche AG | — | Consulting Fee | Cash or cash equivalent | $20,000.00 | General |
| 01/01/2022 | F. Hoffmann-La Roche AG | — | Consulting Fee | Cash or cash equivalent | $24,000.00 | General |
| 06/03/2021 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $1,312.50 | General |
| 01/01/2020 | F. Hoffmann-La Roche AG | Non-Covered Product (Drug) | Consulting Fee | Cash or cash equivalent | $30,000.00 | General |
| Category: None | ||||||
| 12/19/2019 | Novartis Pharma AG | QAW039A_INVESTIGATIONAL_RESPIRATORY (Drug), IGE025A_XOLAIR _RESPIRATORY | Consulting Fee | Cash or cash equivalent | $5,128.00 | General |
| Category: RESPIRATORY | ||||||
| 12/19/2019 | Novartis Pharma AG | QAW039_INVESTIGATIONAL_RESPIRATORY (Drug), IGE025A_XOLAIR _RESPIRATORY | Travel and Lodging | Cash or cash equivalent | $183.16 | General |
| Category: RESPIRATORY | ||||||
| 12/19/2019 | Novartis Pharma AG | QAW039A_INVESTIGATIONAL_RESPIRATORY (Drug), IGE025A_XOLAIR _RESPIRATORY | Food and Beverage | Cash or cash equivalent | $33.37 | General |
| Category: RESPIRATORY | ||||||
| 11/13/2019 | Novartis Pharma AG | QAW039_INVESTIGATIONAL_RESPIRATORY (Drug), IGE025A_XOLAIR _RESPIRATORY | Travel and Lodging | In-kind items and services | $7,941.20 | General |
| Category: RESPIRATORY | ||||||
| 11/13/2019 | Novartis Pharma AG | QAW039_INVESTIGATIONAL_RESPIRATORY (Drug), IGE025A_XOLAIR_RESPIRATORY | Travel and Lodging | In-kind items and services | $105.68 | General |
| Category: RESPIRATORY | ||||||
| 11/13/2019 | Novartis Pharma AG | QAW039_INVESTIGATIONAL_RESPIRATORY (Drug), IGE025A_XOLAIR _RESPIRATORY | Travel and Lodging | In-kind items and services | $92.92 | General |
| Category: RESPIRATORY | ||||||
| 11/12/2019 | Novartis Pharma AG | QAW039_INVESTIGATIONAL_RESPIRATORY (Drug), IGE025A_XOLAIR _RESPIRATORY | Travel and Lodging | In-kind items and services | $92.92 | General |
| Category: RESPIRATORY | ||||||
| 11/11/2019 | Novartis Pharma AG | QAW039_INVESTIGATIONAL_RESPIRATORY (Drug), IGE025A_XOLAIR _RESPIRATORY | Travel and Lodging | In-kind items and services | $52.32 | General |
| Category: RESPIRATORY | ||||||
| 10/01/2019 | F. Hoffmann-La Roche AG | Non-Covered Product (Drug) | Consulting Fee | Cash or cash equivalent | $10,000.00 | General |
| Category: None | ||||||
| 06/15/2019 | F. Hoffmann-La Roche AG | Non-Covered Product (Drug) | Consulting Fee | Cash or cash equivalent | $35,000.00 | General |
| Category: None | ||||||
| 01/01/2019 | F. Hoffmann-La Roche AG | Non-Covered Product (Drug) | Consulting Fee | Cash or cash equivalent | $15,000.00 | General |
| Category: None | ||||||
About Dr. Robert Strieter, MD
Dr. Robert Strieter, MD is a Pulmonary Disease healthcare provider based in Los Angeles, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/20/2006. The National Provider Identifier (NPI) number assigned to this provider is 1871513978.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robert Strieter, MD has received a total of $172,942 in payments from pharmaceutical and medical device companies, with $68,000 received in 2022. These payments were reported across 17 transactions from 3 companies. The most common payment nature is "Consulting Fee" ($164,441).
Practice Information
- Specialty Pulmonary Disease
- Location Los Angeles, CA
- Active Since 07/20/2006
- Last Updated 07/20/2010
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1871513978
Products in Payments
- Non-Covered Product (Drug) $90,000
- QAW039_INVESTIGATIONAL_RESPIRATORY (Drug) $8,468
- QAW039A_INVESTIGATIONAL_RESPIRATORY (Drug) $5,161
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pulmonary Disease Doctors in Los Angeles
Prof. Toby Maher, Md, MD
Pulmonary Disease — Payments: $1.1M
Donald Tashkin, Md, MD
Pulmonary Disease — Payments: $646,650
Rajan Saggar, Md, MD
Pulmonary Disease — Payments: $426,392
John Belperio, Md, MD
Pulmonary Disease — Payments: $308,808
Christopher Cooper, Md, MD
Pulmonary Disease — Payments: $207,817
Roy Artal, M.d, M.D
Pulmonary Disease — Payments: $151,187